360 Series Panel Collection
Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.
Ideal for studying solid tumors, the 360 Series Panel Collection can be used to better understand the biology behind therapeutic response, therapeutic mechanism of action, immune evasion, and the interplay between the tumor and microenvironment. These panels serve as powerful tools for developing novel signatures that correlate with response and/or survival.
- 1,588 unique genes included across all panels
- PAM50, Claudin-Low, & Triple Negative Breast Cancer (TNBC) gene signatures included in the Breast Cancer 360 Panel
- Data Analysis Service for the IO 360 and Breast Cancer 360 Panels provides interactive and customizable reports with signatures scores
- Pairs with GeoMx® Cancer Transcriptome Atlas for comparative spatial RNA profiling
How It Works
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
The Tumor Inflammation Signature1 includes 18 functional genes often associated with the response to PD-1/PD-L1 checkpoint inhibitors. It is embedded into all of the 360 series panels: The PanCancer IO 360 Panel, the Breast Cancer 360 Panel, and the Tumor Signaling 360 Panel.
- Includes four areas of immune biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
- Highlights the complex biology of the host immune microenvironment.
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.
The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.
Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.
Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.